Skip to content

Omegia Softgel Clinical Research Program

Chia Nan University of Pharmacy & Science

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05872178
Enrollment
40
Registered
2023-05-24
Start date
2021-04-15
Completion date
2022-12-31
Last updated
2023-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antioxidative Stress, Eye Strain, Skin Manifestations, Vaginal Disease

Brief summary

Evaluate the improvement of regulation of skin and blood index composition after consumption of Omegia® Softgel

Detailed description

The blood biochemical analysis at Weeks 0 and 12, including Catalase, Tumor necrosis factor-α, Cholesterol, Triglyceride, High-density lipoprotein-Cholesterol and Low-density lipoprotein- Cholesterol. The Skin assessment at Weeks 0, 4 and 12, including Skin brightness, Skin redness sensitivity index, Skin moisture, Skin elasticity, Facial skin pores, Facial skin texture and Skin collagen content.

Interventions

DIETARY_SUPPLEMENTOmegia® Softgel -B

How to use: Take once a day for 12 weeks Subject precautions: If the health products and cosmetic care products used contain sea buckthorn ingredients, stop using them.

DIETARY_SUPPLEMENTOmegia® Softgel -A

How to use: Take once a day for 12 weeks Subject precautions: If the health products and cosmetic care products used contain sea buckthorn ingredients, stop using them.

Sponsors

Chia Nan University of Pharmacy & Science
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
45 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

● Female subjects older than 45 years

Exclusion criteria

* Involuntary subjects * Skin disease, liver cirrhosis or chronic renal failure * Those with known cosmetic, drug or food allergies * Pregnant women and nursing mothers. * Those taking chronic disease medication * The subject has received laser facial treatment, fruit acid facial peeling, long-term sunlight, etc. within four weeks of the test

Design outcomes

Primary

MeasureTime frameDescription
Skin brightnessSubjects will be tested in the 4th weekSkin color difference analyzer (Chroma Meter MM500) was utilized to measure skin brightness. Units: arbitrary units
Skin rednessSubjects will be tested in the 4th weekSkin color difference analyzer (Chroma Meter MM500) was utilized to measure skin redness. Units: arbitrary units
Skin moistureSubjects will be tested in the 4th weekSkin moisture meter (Corneometer CM825) was utilized to measure skin moisture. Units: arbitrary units
Skin elasticitySubjects will be tested in the 4th weekSkin elastometer (Soft Plus) was utilized to measure skin elasticity. Units: arbitrary units
Facial skin poresSubjects will be tested in the 4th weekVISIA Micro-Analysis Skin Image Analyzer was utilized to measure skin pores. Units: arbitrary units
Facial skin textureSubjects will be tested in the 4th weekVISIA Micro-Analysis Skin Image Analyzer was utilized to measure skin texture. Units: arbitrary units
Skin collagen contentSubjects will be tested in the 4th weekSubcutaneous collagen scanner (DermaLab® Series SkinLab Combo) was utilized to measure skin collagen. Units: arbitrary units

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026